Greg Perry's appointment as CFO of Merus N.V. is likely to have a positive short-term impact on the company's stock price. His extensive experience in the biotech industry, including serving on the Merus Board of Directors, will provide valuable insights and financial acumen to the company as it continues to advance its clinical-stage oncology pipeline.